BackgroundCheck.run
Search For

Masoud Mokhtarani, 59725 Castle Rock Rd, Walnut Creek, CA 94598

Known as:
Mosoud Mokhtarani Masoud Marzban Mokhtarani Masoud Masoud I
Related to:
Eddie R Redwine 75

Masoud Mokhtarani Phones & Addresses

725 Castle Rock Rd, Walnut Creek, CA 94598    925-9524209   

429 Walnut Ave, Walnut Creek, CA 94598    925-9524209   

San Diego, CA   

San Francisco, CA   

Clearwater, FL   

Walnut, CA   

Hayward, CA   

725 Castle Rock Rd, Walnut Creek, CA 94598   

Work

Position: Professional/Technical

Education

Degree: High school graduate or higher
Get Report
Control this profile

Mentions for Masoud Mokhtarani

Masoud Mokhtarani resumes & CV records

Resumes

Masoud Mokhtarani Photo 2

Clinical Development Consultant

Location:
8355 Station Village Ln, San Diego, CA 92108
Industry:
Biotechnology
Work:
Curzion Pharmaceutical May 2019 - Apr 2020
Chief Medical Officer Neurovia Jan 2016 - Jul 2018
Chief Medical Officer Hyperion Therapeutics Jul 2008 - Dec 2015
Vp, Clinical Development and Medical Affairs Bay Bio-Pharma Development Jan 2007 - Aug 2008
Principal Limerick Neuroscience Mar 2007 - Apr 2008
Vp, Clinical Affairs Rinat Neuroscience 2005 - 2007
Director Immune Tolerance Network 2002 - 2005
Clinical Scientist Centaur Media Plc Dec 2000 - Dec 2001
Acting Associate Director; Clinical Development Dec 2000 - Dec 2001
Clinical Development Consultant
Education:
University of California, San Francisco 1999 - 2000
University of Tehran 1982 - 1991
Doctor of Medicine, Doctorates, Medicine
Skills:
Clinical Development, Drug Development, Clinical Trials, Gcp, Clinical Research, Pharmacology, Immunology, Fda, Neuroscience, Regulatory Submissions, Medical Affairs, Biostatistics, Protocol, Clinical Study Design, Medicine, Rheumatology, Infectious Diseases, Pharmaceutical Industry, Biotechnology, Oncology, Ctms, Lifesciences, Pharmacovigilance, Life Sciences, U.s. Food and Drug Administration, Biopharmaceuticals, Good Clinical Practice
Languages:
Farsi
Masoud Mokhtarani Photo 3

Masoud Mokhtarani

Publications & IP owners

Us Patents

Methods Of Therapeutic Monitoring Of Nitrogen Scavenging Drugs

US Patent:
2013008, Apr 4, 2013
Filed:
Mar 9, 2012
Appl. No.:
13/417137
Inventors:
Bruce SCHARSCHMIDT - San Francisco CA, US
Masoud Mokhtarani - Walnut Creek CA, US
International Classification:
A61K 31/235
G01N 21/78
C12Q 1/00
A61K 31/192
A61P 7/00
US Classification:
514533, 514570, 514544, 435 4, 436113
Abstract:
The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.

Methods Of Therapeutic Monitoring Of Nitrogen Scavenging Drugs

US Patent:
2013021, Aug 15, 2013
Filed:
Feb 22, 2013
Appl. No.:
13/775000
Inventors:
HYPERION THERAPEUTICS, INC. - , US
Masoud Mokhtarani - Walnut Creek CA, US
Assignee:
HYPERION THERAPEUTICS, INC. - South San Francisco CA
International Classification:
A61K 31/216
US Classification:
514533
Abstract:
The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.

Methods Of Therapeutic Monitoring Of Phenylacetic Acid Prodrugs

US Patent:
2013028, Oct 24, 2013
Filed:
Sep 11, 2012
Appl. No.:
13/610580
Inventors:
Bruce Scharschmidt - San Francisco CA, US
Masoud Mokhtarani - Walnut Creek CA, US
International Classification:
A61K 31/225
A61P 1/16
A61P 13/12
A61K 31/192
US Classification:
514533, 514570
Abstract:
The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated.

Methods For Treating Urea Cycle Disorders

US Patent:
2021000, Jan 7, 2021
Filed:
Jul 14, 2020
Appl. No.:
16/928985
Inventors:
- Lake Forest IL, US
Masoud MOKHTARANI - Walnut Creek CA, US
International Classification:
A61K 31/216
A61K 45/06
A61P 3/00
A61K 31/5517
A61K 31/415
Abstract:
Provided are methods of administering glycerol phenylbutyrate to a patient in need thereof, wherein said patient is also being treated with a CYP3A4 substrate having a narrow therapeutic index, midazolam or a pharmaceutically acceptable salt thereof, or celecoxib.

Methods Of Therapeutic Monitoring Of Nitrogen Scavenging Drugs

US Patent:
2021000, Jan 7, 2021
Filed:
Mar 10, 2020
Appl. No.:
16/814549
Inventors:
- Lake Forest IL, US
Masoud MOKHTARANI - Walnut Creek CA, US
International Classification:
A61K 31/235
A61K 9/00
G01N 33/84
G01N 33/49
A61K 31/216
G01N 31/22
Abstract:
The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.

Methods Of Treating Urea Cycle Disorders

US Patent:
2020040, Dec 31, 2020
Filed:
Mar 6, 2020
Appl. No.:
16/811861
Inventors:
- Lake Forest IL, US
Masoud MOKHTARANI - Walnut Creek CA, US
International Classification:
A61K 31/235
A61K 31/192
G01N 33/50
G01N 33/68
Abstract:
The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age.

Treatment Of Urea Cycle Disorders In Neonates And Infants

US Patent:
2020039, Dec 17, 2020
Filed:
Apr 27, 2020
Appl. No.:
16/859019
Inventors:
- Lake Forest IL, US
Masoud MOKHTARANI - Walnut Creek CA, US
International Classification:
A61K 31/216
A61K 9/00
G01N 33/84
Abstract:
Nitrogen scavenging drugs such as glycerol phenylbutyrate can be administered safely to infants and toddlers with urea cycle disorders by adjusting the dosage based on one or more biomarkers selected from the group consisting of urinary-PAGN and plasma PAA:PAGN ratio.

Methods Of Therapeutic Monitoring Of Nitrogen Scavenging Drugs

US Patent:
2019012, May 2, 2019
Filed:
Nov 16, 2018
Appl. No.:
16/194061
Inventors:
- Lake Forest IL, US
Masoud MOKHTARANI - Walnut Creek CA, US
International Classification:
A61K 31/235
G01N 33/49
G01N 33/84
A61K 31/216
G01N 31/22
A61K 9/00
Abstract:
The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.

Possible Relatives

Masoud Jafari  Masoud M Kashani  Masoud Emami  Masoud Hassani  Masoud Mikhail  Masoud F Kermani  Masoud Khatibi  Masoud Bokaie  Masoud K Khansefid 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.